Liposomes conjugated with anti-RET antibodies may have potential applications in the treatment of lung cancer. This strategy utilizes liposomes as drug delivery systems, enhancing therapeutic efficacy by targeting specific antibodies (such as anti-RET antibodies) to non-small cell lung cancer (NSCLC) cells. This type of nanotechnology shows significant promise in cancer treatment, but it also faces challenges such as drug efficacy and delivery efficiency.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
MOB-844-F(E) | Recombinant Anti-RET Antibody Fab Fragment | RIA, WB, FuncS | Fab |
MHH-844-F(E) | Recombinant Human Anti-RET Antibody Fab Fragment | ELISA, WB, FC, FuncS | Fab |
There are currently no Customer reviews or questions for VS-1024-FY40. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.